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Abstract
Background: People with multiple sclerosis have problems with memory and attention. Cognitive rehabilitation is
a structured set of therapeutic activities designed to retrain an individual’s memory and other cognitive functions.
Cognitive rehabilitation may be provided to teach people strategies to cope with these problems, in order to
reduce the impact on everyday life. The effectiveness of cognitive rehabilitation for people with multiple sclerosis
has not been established.
Methods: This is a multi-centre, randomised controlled trial investigating the clinical and cost-effectiveness of a
group-based cognitive rehabilitation programme for attention and memory problems for people with multiple
sclerosis. Four hundred people with multiple sclerosis will be randomised from at least four centres. Participants will
be eligible if they have memory problems, are 18 to 69 years of age, are able to travel to attend group sessions and
give informed consent. Participants will be randomised in a ratio of 6:5 to the group rehabilitation intervention plus
usual care or usual care alone. Intervention groups will receive 10 weekly sessions of a manualised cognitive
rehabilitation programme. The intervention will include both restitution strategies to retrain impaired attention and
memory functions and compensation strategies to enable participants to cope with their cognitive problems.
All participants will receive a follow-up questionnaire and an assessment by a research assistant at 6 and 12 months
after randomisation. The primary outcome is the Multiple Sclerosis Impact Scale (MSIS) Psychological subscale at
12 months. Secondary outcomes include the Everyday Memory Questionnaire, General Health Questionnaire-30,
EQ-5D and a service use questionnaire from participants, and the Everyday Memory Questionnaire-relative
version and Carer Strain Index from a relative or friend. The primary analysis will be based on intention to treat.
A mixed-model regression analysis of the MSIS Psychological subscale at 12 months will be used to estimate the
effect of the group cognitive rehabilitation programme.
Discussion: The study will provide evidence regarding the clinical and cost-effectiveness of a group-based
cognitive rehabilitation programme for attention and memory problems in people with multiple sclerosis.
Trial registration: ISRCTN09697576. Registered 14 August 2014.
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Background
Cognitive rehabilitation is a structured set of therapeutic
activities designed to retrain an individual’s memory and
other cognitive functions. A narrative review [1] re-
ported that cognitive rehabilitation was beneficial for
treating cognitive deficits following brain damage. There
are recommendations for the provision of cognitive re-
habilitation for people with multiple sclerosis (MS) in
the European Federation of Neurological Societies
Guidelines on cognitive rehabilitation [2] and National
Service Framework for Long term Conditions [3]. Some
randomised controlled trials (RCTs) have demonstrated
the effectiveness of cognitive rehabilitation in people
with MS [4–8] but most evidence comes from single
case experimental design studies, non-RCTs, and small
pilot RCTs [9]. Systematic reviews on cognitive rehabili-
tation have not found evidence to support or refute the
effectiveness of cognitive rehabilitation for people with
MS [10–13]. However, the narrative review by O’Brien
et al. [9] found low-level evidence for positive effects of
neuropsychological rehabilitation in MS and suggested
that more high quality trials were needed.
Two small scale pilot RCTs used similar cognitive re-
habilitation programmes. The ReMIND trial [14] (n = 72)
evaluated the effectiveness of group memory rehabilitation
programmes in patients with memory problems, many of
whom had MS (n = 39). Participants were randomly allo-
cated to one of three programmes: compensation strategy
training, restitution, or a self-help control. Both quantita-
tive and qualitative data from the study [14, 15] indicated
the interventions were worthy of further evaluation. The
ReMIND-MS trial [16] was a modified version of the cog-
nitive rehabilitation group intervention, combining resti-
tution and compensation strategies, compared with a
usual care control with people with MS (n = 48). The re-
sults showed a significant effect on mood, favouring the
intervention group. These two pilot RCTs have informed
the sample size calculations and assessment and treatment
methods for this present trial.
This present trial has been designed to assess the clin-
ical and cost-effectiveness of a group cognitive rehabili-
tation programme, on the basis of recent research
suggestions [17], Cochrane reviews [11, 12], our own
pilot studies [14, 16], current clinical guidelines [2, 3]
and clinical practice in the UK.
Methods
Trial objectives
The primary objective is to determine whether attending
a group cognitive rehabilitation programme (the inter-
vention), in addition to usual care, is associated with re-
duced psychological impact of MS on quality of life, as
measured on the MS Impact Scale (MSIS) Psychological
Subscale (MSIS-Psy) [18] when compared to usual care
alone (control). The secondary objectives are to assess
cost-effectiveness of the intervention, and whether the
intervention is associated with improvements in partici-
pants’ attention and memory abilities, self-reported at-
tention, memory problems in daily life, mood, fatigue,
employment status and carer strain.
Trial design
This is a multi-centre, parallel group, RCT.
Ethical approval
Ethical approval was granted by NRES Committee West
Midlands on 1 September 2014 (reference 14/WM/
1083).
Site and participant recruitment
The study will be conducted in at least four centres in
the UK.
Participants will be identified through National Health
Service hospitals, rehabilitation centres and charities
(e.g. MS Society branches). A letter will be sent to indi-
viduals, identified as potential participants, by a member
of the clinical team, which will include a participant in-
formation sheet, a consent form and a pre-paid reply en-
velope. Self-referral will also be possible for those who
access public facing information, on the study website,
newsletters and posters. Recruitment will take place over
2 years.
Informed consent
Written informed consent will be obtained by an assist-
ant psychologist. Participants will be informed that their
participation is entirely voluntary and they are free to
withdraw at any time; in the event of their withdrawal,
any data collected up until that point would be kept by
the research team. Participants will be asked whether
they consent to a follow-up interview to assess treatment
acceptability and will be informed that, if allocated to
the intervention group, sessions may be video recorded
to ensure treatment fidelity. A letter will be sent to the
General Practitioners of consenting participants inform-
ing them of their patients’ involvement in the trial.
Inclusion criteria
People with MS are eligible for the trial if they are aged
18 to 69 years, have relapsing remitting or progressive
MS, diagnosed at least 3 months prior to the baseline as-
sessment, report having cognitive problems as deter-
mined by a cut-off score >27 on the patient version of
the Multiple Sclerosis Neuropsychological Screening
Questionnaire (MSNQ) [19], have cognitive deficits, de-
fined as performance more than one standard deviation
below the mean of healthy controls corrected for age
and education [20] on the Brief Repeatable Battery of
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Neuropsychological Tests (BRBN) [21], are able to travel
to one of the centres to attend group sessions, are able
to speak English sufficiently to complete the cognitive
assessments and take part in group sessions, and give in-
formed consent.
Exclusion criteria
Potential participants will be excluded if they have vision
or hearing problems, such that they are unable to
complete the cognitive assessments, have concurrent se-
vere medical or psychiatric conditions, which would pre-
vent them from engaging in treatment, or are involved
in other psychological intervention trials.
Initial screening assessment
At the first appointment, the assistant psychologist will
explain the study and make clear that the initial screen-
ing assessments are required to check that the partici-
pant meets the inclusion criteria and to obtain some
baseline data for those who are eligible. Demographic in-
formation recorded will include gender, date of birth,
ethnicity, years of education, living arrangements, mari-
tal status and employment status.
The following assessments will be conducted at the
initial screening:
 Multiple Sclerosis Neuropsychological Screening
Questionnaire (MSNQ) [19]
 The Brief Repeatable Battery of Neuropsychological
Tests (BRBN) [21]
 Guy’s Neurological Disability Scale [22]
The results from the MSNQ and BRBN will be used to
assess whether the participant meets the inclusion cri-
teria. Following screening, participants will be informed
whether they meet the study criteria. Those who do not
will be notified and thanked for their interest in the
study.
Those who meet the inclusion criteria will be given
questionnaires to complete in their own time. These will
be collected at the baseline assessment visit:
 MS Impact scale version 2 (MSIS) [18]
 Everyday Memory Questionnaire (EMQ) patient
version [23]
 General Health Questionnaire 30 item (GHQ30) [24]
 Fatigue Severity Scale (FSS) [25]
Participants will be sent an information sheet for a
friend or relative with an EMQ relative version to be
completed and returned.
At the baseline visit the following assessments will be
conducted by the assistant psychologist:
 Euroquol five dimensions five levels (EQ-5D-5L) [26]
 Use of Health and Social Services Questionnaire,
which also includes medication and medication
changes.
 Doors and People [27]
 Trail Making Test [28]
The assistant psychologist will check the participant’s
availability to attend groups on certain days, should they
be randomised to receive the intervention. Participants
will only be randomised if they can attend on the days
that groups are scheduled. Those unable to attend on
scheduled days will be held in reserve until such time
that a new group, matching their availability, is formed.
During the period participants are waiting for a suffi-
cient number of other participants to be included in a
group, the assistant psychologist will remain in regular
contact to keep individuals aware of likely timescales.
Participant outcome assessments
Outcomes will be assessed at 6 and 12 months after ran-
domisation to assess immediate and long-term effects of
the intervention. The primary follow-up is 12 months
after randomisation. The NHS number will be supplied
to the Medical Research Information Service to allow a
mortality check prior to contact for follow-up.
The primary outcome is the psychological impact of
MS, measured using the MSIS-Psy [18].
Secondary outcomes are:
 Memory problems in everyday life, as measured
using the EMQ patient and relative versions [23]
 Mood, as measured using the GHQ30 [24]
 Fatigue, as measured using the FSS [25]
 Quality of Life, as measured using the EQ-5D-5L [26]
 Attention and memory abilities, as measured by a
cognitive test battery
○ BRBN [21]
○ Doors and People [27]
○ Trail Making Test [28]
 Physical impact of MS, as measured using the MSIS
Physical Subscale (MSIS-Phys) [18]
 Cost-effectiveness, with costs measured by the Use
of Health and Social Services Questionnaire
compared with the primary and secondary
outcomes, including a cost per quality-adjusted life
year analysis using the EQ-5D-5L [26]
 Employment status, as measured as part of the Use
of Health and Social Services Questionnaire
 Carer strain, as measured using the Modified Carer
Strain Index [29]
In addition, the level of disability, as measured by the
Guys Neurological Disability Scale (GNDS) [22] and
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number of reported MS relapses in the previous
6 months, will be recorded.
Participants will receive a questionnaire pack, which
includes the MSIS, EMQ, GHQ30, FSS and GNDS, to
complete in their own time. They may request help in
completing these questionnaires if necessary. A research
assistant (RA), who is unaware of the group allocation,
will check whether the questionnaires have been com-
pleted prior to the assessment visit. If they have not, the
RA will ask the participant to complete them during the
visit and will also conduct the cognitive assessments,
Use of Health and Social Services Questionnaire and the
EQ-5D-5L [26].
Minimisation of bias
Steps will be undertaken to reduce the risk of bias in this
trial. Allocation will be randomly assigned and concealed
using an automated web-based system operated by Not-
tingham Clinical Trials Unit (NCTU). There is a single
primary outcome (MSIS-Psy) [18] and all outcomes spe-
cified in the protocol will be analysed and reported.
While the primary outcome and some secondary out-
comes are self-reported and therefore not blinded, the
cognitive tests will be assessed by a researcher who will
be blinded to treatment allocation. Collection of out-
come data will be attempted from every randomised par-
ticipant not known to have died at the time of follow-up
and who has not withdrawn consent, regardless of ad-
herence to allocated treatment. It is anticipated that
there will be some non-collection of primary outcome
data, and while the primary intention-to-treat analyses
will be without imputation of missing data, sensitivity
analyses will investigate various assumptions about the
missing data.
The participants and assistant psychologists will not
be blind to the allocated treatment. To prevent unblind-
ing, the RA will request participants completing out-
come assessments not to discuss any aspect of being
involved with the study. The RA will also be required to
guess the treatment allocation for each participant and
this will be compared later to the actual allocation, to
determine the degree of unblinding.
Randomisation
Participants will be individually randomised to interven-
tion or control on a 6:5 ratio to allow for clustering in
the intervention arm. Allocation will be stratified by re-
cruitment site, and minimised by MS type (relapsing–
remitting or progressive) and gender. Randomisation
will take place once there are 9–11 individuals who
have consented and who are able to attend the same
therapy group (location, day of the week and time of
day) should they be randomised to receive it. The allo-
cation algorithm will be created by the NCTU in
accordance with their standard operating procedure
and held on a secure server. Assistant psychologists at
each site will use a remote, internet-based randomisa-
tion system to obtain treatment allocations for each
participant. Access to the sequence will be confined to
the NCTU Information Technology Manager. The se-
quence of treatment allocations will be concealed from
the study statistician until all participants have been al-
located, and recruitment, data collection and all other
study-related assessments are complete.
Duration of participant participation
Figure 1 shows the expected progress of the study. Par-
ticipants are in the study for approximately 14 months
from the initial screening assessment (12 months from
randomisation). Participants will leave the study when
they have completed the 12 month follow-up.
Cognitive rehabilitation
Cognitive rehabilitation is a structured set of therapeutic
activities designed to improve cognitive function and to
reduce the impact of cognitive impairment on daily life.
The emphasis of the intervention will be on identifying
the most appropriate strategies to help individuals over-
come their cognitive problems and in providing partici-
pants with a range of techniques, which they can use
and adapt according to their needs.
Each rehabilitation group will be led by an assistant
psychologist under the supervision of a clinical psych-
ologist. Assistant psychologists will be trained centrally
on all study-related procedures, including the delivery of
the intervention, to ensure consistency across sites and
adherence to the protocol. Each group will consist of
four to six participants. Participants will receive 10
group memory rehabilitation sessions (1.5 hours long,
including a break, once a week for 10 weeks). The con-
tent of sessions will be as defined in a treatment manual,
which was developed and tested in the previous study
[16]. The intervention will include restitution strategies
to retrain memory functions, attention retraining and
strategies to improve encoding and retrieval. Compensa-
tion strategies will also be taught, including internal
mnemonics (such as chunking, use of first letter cues,
rhymes), use of external devices (such as diaries, mobile
phones, calendars) and ways of coping with memory
problems. The programme will be tailored to each par-
ticipant’s cognitive status, depending on the impairments
identified during the baseline assessment, while main-
taining a systematic approach to working on attention
and memory functions. Each session will end with the
setting of homework assignments to help participants
practice the strategies learnt in the group sessions in
their daily life. These will be reviewed at the following
session. Carers and family members will be invited to
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attend the last session, if participants agree, which serves
as a summary of the previous sessions.
Control group (usual care)
Participants will receive their usual clinical care. In the
standard NHS care pathway, people with MS with cogni-
tive problems may get general advice from MS nurses
and occupational therapists on how to manage any cog-
nitive difficulties. There are information sheets available
on web pages of MS charities which include suggestions
for coping. However, usual care does not normally in-
clude any specific intervention for cognitive problems or
cognitive rehabilitation.
All other clinical services will be available as usual for
both groups. This may include referral to employment
rehabilitation services, self-help groups or support from
specialist charities, such as the MS Society. Any add-
itional input (including psychological or medical inter-
ventions) participants receive during the study will be
recorded from the Use of Health and Social Services
questionnaire.
Compliance with interventions
The assistant psychologist will record whether partici-
pants attend each of the treatment sessions and the rea-
sons why any sessions are not attended, if known.
Fig. 1 CONSORT diagram. BRBN Brief Repeatable Battery of Neuropsychological Tests, MS Multiple sclerosis, MSNQ Multiple Sclerosis
Neuropsychological Screening Questionnaire
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To ensure the fidelity of the intervention, at least
twenty sessions will be video recorded. Sessions will be
purposively pre-selected for recording in order to in-
clude sessions from the beginning, middle and end of
the 10-week course and recordings will be made across
the intervention period. Practices for video recording
will draw upon guidance on minimising intrusiveness of
the recording [30, 31]. Methods used in previous work
will be used to analyse the content of training within re-
habilitation contexts [32, 33]. Two independent asses-
sors will separately analyse the video recordings using a
customised score sheet to capture a variety of key ele-
ments spanning all aspects of the intervention. Assessors
will code these factors as present or absent over a series
of time intervals. This method has successfully been
used in the pilot study to determine treatment fidelity
without disrupting the group sessions [33].
Sample size and justification
Our sample size estimate is based on analysis of the
MSIS-Psy [18] at 12 months post-randomisation. A clin-
ically meaningful effect using this outcome is probably
in the range 3–3.5. In the pilot study, the 95 % confi-
dence interval for the difference between intervention
and usual care was −1 to +8, indicating that the inter-
vention has the potential to have an effect that is
regarded as clinically worthwhile. The common standard
deviation in the pilot study was 7.5 (using version 1 of
the MSIS-Psy scored 9 to 45). However, we expect the
standard deviation will be higher in the present trial as
the sample for the pilot study were all recruited from a
single outpatient rehabilitation unit, whereas this pro-
posed sample will include people who have been re-
cruited from multiple settings.
Based on a two-sample test, 143 participants per arm
are required for analysis in order to detect a difference
of 3 points on the MSIS-Psy, assuming a standard devi-
ation of 9 (effect size 0.33), with 80 % power, and 5 %
two-sided alpha. However, a clustering effect may occur
in the intervention arm due to the intervention being
delivered in groups. We estimate this clustering effect to
be 0.1 [13]. Design and analysis issues in partially clus-
tered clinical trials have been reported [34]. Based on an
average cluster size of five evaluable participants (those
providing primary outcome data at 12 months after
randomisation), and an intracluster correlation coeffi-
cient (ICC) of 0.1 in the intervention arm, a total of
336 evaluable patients would provide 80 % power to
detect such a difference (184 to intervention and 154 to
usual care). Additionally, the optimal allocation ratio
depends on the cluster size and the ICC. In this case,
we will allocate participants in a ratio of 6:5 in favour
of the intervention arm.
Data from the pilot study suggested non-collection of
primary outcome data in 8 % of participants. However
because of the wider recruitment strategy and from evi-
dence of recruitment to other related studies [35, 36],
we estimate it will be 15 %. We will therefore aim to
randomise a total of 400 participants (216 to interven-
tion and 184 to usual care).
Version 2 of the MSIS-Psy will be used in this study
with scores ranging between 9 and 36. The standard de-
viation of the MSIS-Psy version 2 in the UK South West
Impact of Multiple Sclerosis cohort was 6.4 [37]. If the
standard deviation in this study is between 6 and 9, dif-
ferences of between 2 and 3 points on version 2 of the
MSIS-Psy will be detectable based on the effect size spe-
cified above, with assumed similar clinical importance as
for version 1.
Statistical analysis
The analysis and presentation of the trial will be in ac-
cordance with CONSORT guidelines [38], with the pri-
mary between-group comparisons based on analysing
participants as randomised without imputation of miss-
ing data. A full analysis plan will be developed prior to
completion of data collection and discussed and agreed
with the Trial Steering Committee and Data Monitoring
Committee.
Descriptive statistics of demographic and clinical mea-
sures at baseline will be used to examine balance be-
tween those randomised to intervention and control.
The primary analysis will employ a mixed effects linear
regression model of the MSIS-Psy outcome at 12 months
adjusted for baseline value and stratification/minimisa-
tion variables, and taking appropriate account of cluster-
ing by therapy group. Distributions of raw outcome
scores and regression model residuals will be examined
and the data suitably transformed or a non-parametric
analysis employed if necessary. For a parametric analysis,
the comparison will be presented as an adjusted differ-
ence in mean MSIS-Psy score along with 95 % confi-
dence intervals and exact p value. We will investigate
whether further adjustment for any variables exhibiting
marked imbalance at baseline influences the primary
findings.
Earlier effects on the primary outcome will be investi-
gated in a secondary analysis by comparing the arms at
6 months after randomisation. Similar analyses using ap-
propriate regression models depending on outcome type
will be conducted for secondary outcomes. Additional,
secondary analyses of the primary outcome will take
three general forms. First, the influence of missing data
will be investigated using sensitivity analyses. Second,
the effect of adherence to treatment will be investigated
using allocation respecting methods such as complier
averaged causal effects modelling using instrumental
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variable regression. Third, appropriate interaction terms
will be entered into the primary regression analyses for
MSIS-Psy in order to conduct pre-specified subgroup
analyses according to MS type, baseline MSNQ, and
baseline Doors and People scores. Since the trial is pow-
ered to detect overall differences between the groups ra-
ther than interactions of this kind, the results of these
exploratory analyses will be presented using confidence
intervals and interpreted with due caution.
Health economic evaluation
The cost-effectiveness will be assessed from the perspec-
tive of the UK National Health Service and personal so-
cial services. The costs associated with the intervention
will be determined by calculating the cost of staff time,
materials and travel costs for providing the intervention.
These will be compared with changes in the number of
visits to General Practitioners, hospital, prescribed medi-
cation, and social services contacts in the intervention
and control groups during the investigation. The costs
will be compared with the outcomes generated and a
series of incremental cost-effectiveness ratios computed,
including a cost/quality-adjusted life year analysis, based
on changes in EQ-5D. A series of one-way sensitivity
analyses will be undertaken to determine the extent to
which baseline findings change in light of parameter
variation. Given the limited time duration of the study
and follow-up, a decision analytic model will be con-
structed to determine the cost-effectiveness of the inter-
vention from a lifetime perspective. A series of scenarios
will be constructed to reflect the extent to which differ-
ential outcomes can be predicted to continue over lon-
ger time periods, using expert opinion and information
available in the literature. A probabilistic sensitivity ana-
lysis will be carried out to determine the extent to which
the intervention can be regarded as representing value
for money.
Assessment of safety and adverse events
The risks of taking part in the study have been assessed
as low. There are, however, non-specific risks for partici-
pants involved in travelling to the research sites. Also
participants may experience some distress if they find
they are not performing as well as they think they
should on cognitive assessments. However, distress
caused in this way is considered very unlikely, and any
distress caused is likely to be mild. This distress will be
managed by the assistant psychologists who will be
qualified to deal with such situations, and make neces-
sary referrals to the participant’s General Practitioner, if
needed. For the intervention group, this will also be
dealt with during the course of the intervention. As the
risk overall has been assessed as low, no adverse events
or serious adverse events will be reported for this study.
However, as a safety outcome, the number of partici-
pants who show an increase in scores on the GHQ30
greater than 30 points between baseline and 6-month as-
sessment will be monitored by the Data Monitoring
Committee. In addition, adverse outcomes, such as
hospitalisation and distress, will be recorded.
Participants who withdraw
No withdrawal criteria have been specified, and partici-
pants have the right to withdraw from the study at any
time. If possible, the reasons for leaving the study will be
recorded, but participants are not obliged to give rea-
sons. Participants will be assured that withdrawal will
not affect the care they receive. They will be informed at
the start of the study that data collected up to the point
of withdrawal will be retained and may be used in the
final analysis. There will be no replacement of partici-
pants who withdraw.
All reasonable attempts will be made to contact any
participant lost to follow-up during the course of the
study in order to complete assessments.
Feedback interviews
A feedback interview will be conducted between the
6- and 12-month appointments, with 32 purposefully
selected and willing participants, 16 from each group.
This will include four intervention and four control
participants from each participating centre. The ‘max-
imum-variation’ selection strategy will be designed to
include participants with varying levels of memory im-
pairments, and with varying social circumstances. The
interviews will be conducted by a PhD student who
will not be involved with the participants’ treatment
or outcome assessment, thereby reducing social desir-
ability response bias. The PhD student will become
aware of the group allocations during the interview so
will not be blind to the intervention. The interview
will be audio recorded using a digital recorder, tran-
scribed, and analysed using a thematic analysis, fol-
lowing the protocol prescribed by Braun and Clarke
[39]. Participant consent for the interviews will be
sought separately. The interviews will provide import-
ant feedback on participants’ perception of their pro-
gress and, for those in the intervention groups, the
quality of the intervention provided, and will serve as
a process measure. Insights from this qualitative ana-
lysis will serve to inform developments of the inter-
vention programme in the future and to generate
user-oriented proposals about areas for further investi-
gations. For those in the control group the interviews
will provide confirmation of the nature of usual care
received.
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Criteria for terminating the study
The study maybe stopped as a whole because of a
change in opinion of the Research Ethics Committee,
safety concerns or issues with study conduct at the dis-
cretion of the sponsor.
Trial management
A Trial Management Group (TMG) will be convened
and meet regularly. This group will be in charge of the
everyday running of the trial. A Trial Steering Commit-
tee (TSC) will oversee the conduct of the study and will
have an independent chair. Two service user representa-
tives will be members of this group who will advise on
recruitment strategies, monitor progress with recruit-
ment, and check adherence to the study protocol. Ob-
servers from the National Institute for Health Research,
Health Technology Assessment programme (the funder)
will be invited to TSC meetings. The Data Monitoring
Committee will be an independent group, the members
of which have no other involvement with the study.
Members of this committee will include rehabilitation
professionals and an experienced study statistician. It
will safeguard the interests of trial participants, with par-
ticular reference to safety and the efficacy of the inter-
vention, monitor the overall progress and conduct of the
trial and assist and advise the investigators so as to pro-
tect the validity and credibility of the trial.
Service user involvement
Our service user representative (MM) has MS and cog-
nitive problems. Her role has been to advise on recruit-
ment and dissemination options, and she will contribute
to the lay summary of the project. This service user will
sit on the TMG. Two other service user representatives
will be recruited to the TSC from the MS Society. An-
other service user will review participant information
sheets and any documents that will be read by partici-
pants. They will also contribute to dissemination to ser-
vice users. Service users will contribute to project
management decisions, recruitment, consent (the devel-
opment of participant information sheets), data gather-
ing (through developing participant information leaflets
explaining the study), interpretation of findings (through
the development of recommendations for practice and
patient information leaflets about therapy), and dissem-
ination of the findings through existing networks.
Definition of a protocol deviation
A protocol deviation is an unanticipated or uninten-
tional divergence or departure from the expected con-
duct of a study inconsistent with the protocol, consent
document or other study procedures. All protocol devia-
tions will be recorded on the electronic case report form
by local investigator staff.
Discussion
This study was conceptualised in response to a commis-
sioned call for studies of cognitive rehabilitation for
people with MS. Based on our pilot work [14] and feed-
back from participants [15] we decided to have a usual
care control group, as having a self-help control group
was difficult to organise and problematic to facilitate.
Our choice of primary outcome measure was based on
the need to consider the impact of cognitive problems
on everyday life. We have retained both objective mea-
sures of attention and memory and self-reported mea-
sures, but these are secondary outcomes. Most objective
measures have poor ecological validity.
The content of the intervention is based on a treat-
ment manual, which includes the description of each
session and suggested homework tasks. The design was
pragmatic and reflects a balance between what it is de-
sirable to cover in terms of teaching people strategies to
cope with memory problems, yet at the same time being
of sufficiently low intensity that it could be delivered in
clinical services for people with MS if found to be effect-
ive. The sessions include discussion, as it is hoped that
participants will learn from the experience of others.
Therefore, it will not be possible to document in detail
the exact content of the intervention and time spent on
individual activities. However, the intervention is de-
signed to be individualised according to the participants’
cognitive problems and reflects clinical practice, which
is appropriate for a pragmatic trial. There is also video
recording of a sample of sessions so that it will be pos-
sible to check that the intervention was delivered ac-
cording to the manual.
We anticipate that one of the biggest challenges to re-
cruitment to this study will be potential participants’ own
memory problems. Even those individuals interested in
taking part in this trial may forget to respond to our invi-
tation letter. To address this, we have ethics approval to
include a single telephone call to follow-up non-
responders to enquire whether they remember receiving
the letter and whether they would like to participate.
Trial status
The first centre was open to recruitment on 1 March
2015 and the first participant consented on 20 March
2015. At the time of resubmission, 80 people have con-
sented and 39 have been randomised. Recruitment is
due to finish on 28 February 2017.
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BRBN: Brief Repeatable Battery of Neuropsychological Tests; EMQ: Everyday
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